Measles vaccination and antibody response in autism spectrum disorders

¹ Newcomen Centre, Guy's & St Thomas' NHS Trust, United Kingdom
² University of Manchester, United Kingdom
³ Insitute of Psychiatry, King's College London, United Kingdom
⁴ University College London Institute of Child Health, United Kingdom
⁵ John Radcliffe Hospital Oxford, United Kingdom
⁶ University of Reading, United Kingdom
⁷ Chatswood Assessment Centre, Sydney, Australia
⁸ National Institute of Biological Standards and Control, United Kingdom
⁹ Health Protection Agency, United Kingdom

^* To whom correspondence should be addressed. E-mail: gillian.baird{at}gstt.nhs.uk.

Accepted 9 October 2007

	Abstract

Objective: To test the hypothesis that measles vaccination was involved in the pathogenesis of ASD as evidenced by signs of a persistent measles infection or abnormally persistent immune response shown by circulating measles virus or raised antibody titres in MMR vaccinated children with ASD compared with controls .

Design: Case-control study community based

Methods: A community sample of vaccinated children aged 10-12 years in the UK with ASD (N=98) and two control groups of similar age, one with special educational needs but no ASD (N=52) and one typically developing group (N=90), were tested for measles virus and antibody response to measles in serum.

Results: No difference was found between cases and controls for measles antibody response. There was no dose response relationship between autism symptoms and antibody levels. Measles virus nucleic acid was amplified by RT-PCR in PMBC from one case with autism and two typically developing children. There was no evidence of a differential response to measles virus or the measles component of the MMR in children with ASD, with or without regression, and controls who had either one or two doses of MMR. Only one child from the control group had clinical symptoms of a possible enterocolitis.

Keywords: Autism, Autism spectrum disorders, MMR vaccination, SNAP

eLetters: